NCT04605575: Pyrotinib Plus Vinorelbine in Participants With HER2-positive Previously Treated Locally Advanced or Metastatic Breast Cancer

Breast Cancer Type: HER2+
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Tyrosine-Kinase Inhibitor, Chemotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years to 70 Years (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with untreated symptomatic brain metastasis; Patients with a history of HER2 targeting tyrosine kinase inhibitors (e.g. pyrotinib, Tukysa/tucatinib, Nerlynx/neratinib, Tykerb/lapatinib); Patients without prior treatment that includes both a taxane, alone or in combination with another agent, & Herceptin/trastuzumab

Comments are closed.

Up ↑